Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus by Emad Dawoud, Fathi Azribi, Aref Chehal, Shaheenah Dawood, Syed Hammad Tirmazy, Dina Hamza, Hassan Jaafar, Hussam Marashi

Subjects: “…HER2…”
Get full text

HER2 与膀胱尿路上皮癌临床病理分子分型的相关性 by 王婧婧, 吴景, 尹恬恬, 何杰

Subjects: Get full text

ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer by Shufen Mo, Haiming Zhong, Weiping Dai, Yuanyuan Li, Bin Qi, Taidong Li, Yongguang Cai

Subjects: “…HER2-positive breast cancer…”
Get full text

Clinical Effect of "RuningⅡ" and Massage along Meridians Treatment on Patients with HER-2 Over-expressing Breast Cancer in Postoperative Rehabilitation Period by Shengfang HU, Hongfeng CHEN, Deming LU

Subjects: Get full text

A versatile gold leaf immunosensor with a novel surface functionalization strategy based on protein L and trastuzumab for HER2 detection by Ivana Kundacina, Silvia Schobesberger, Stefan Kittler, Helena Thumfart, Oliver Spadiut, Peter Ertl, Nikola Ž. Knežević, Vasa Radonic

Subjects: Get full text

Leveraging computational approaches in identifying novel HER-2 + breast cancer potential therapeutics: integrating virtual screening and molecular dynamics simulation by Olawale Quadri Bolaji, Temitope Isaac Adelusi, Taiwo Ooreoluwa Ojo, Ibrahim Damilare Boyenle, Abdul-Quddus Kehinde Oyedele, Taiwo Temitope Ogunjobi, Adegboye Oyewole Oyaronbi, Sukurat Oluwatoyin Ayoola, Abdeen Tunde Ogunlana

Subjects: Get full text

Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database... by Sarah Waliany, Misako Nagasaka, Leah Park, Clara Lam, Zoe Jiang, Feng Lin, Joel W. Neal

Subjects: Get full text

Surgical delay-associated mortality risk varies by subtype in loco-regional breast cancer patients in SEER-Medicare by Macall Leslie Salewon, Rashmi Pathak, William C. Dooley, Ronald A. Squires, Hallgeir Rui, Inna Chervoneva, Takemi Tanaka

Subjects: Get full text

The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis by Shiwei Liu, Miao Yu, Exian Mou, Meihua Wang, Shuanghua Liu, Li Xia, Hui Li, Hao Tang, Yajing Feng, Xin Yu, Kun Mi, Hao Wang

Subjects: Get full text

The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy by Huihui Guo, Hongsheng Xie, Yuanyuan Huang, Junxiang Jia, Xiangfei Kong, Qingliang Yang, Shun Gai, Wenjun Li, Lu Bai, Lingli Zhang, Xiaoxiao Chen, Zhicang Ye, Hangbo Ye, Linyao Zhao, Yifang Xu, Yong Du, Xiuzhen Zhang, Miaomiao Chen, Xiaomai Zhou, Robert Y. Zhao

Subjects: Get full text

Precise HER2 Protein Degradation via Peptide‐Conjugated Photodynamic Therapy for Enhanced Breast Cancer Immunotherapy by Changyong Guo, Fei Gao, Guoyuan Wu, Jinqiu Li, Chunquan Sheng, Shipeng He, Honggang Hu

Subjects: Get full text

Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study by Yan Chen, Yu Qiu, Haoyang Shen, Shuixin Yan, Jiadi Li, Weizhu Wu

Subjects: “…HER2-positive breast cancer…”
Get full text

Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients by Tzu-Chun Cheng, Mien-Chie Hung, Lu-Hai Wang, Shih-Hsin Tu, Chih-Hsiung Wu, Yun Yen, Chi-Long Chen, Jacqueline Whang-Peng, Wen-Jui Lee, You-Cheng Liao, Yu-Ching Lee, Min-Hsiung Pan, Hui-Kuan Lin, Huey-En Tzeng, Peixuan Guo, Cheng-Ying Chu, Li-Ching Chen, Yuan-Soon Ho

Subjects: “…Anti-HER2 therapy responder…”
Get full text

Case report: Unraveling a unique case of male occult breast cancer with axillary intricacies and a comprehensive literature dive by Xintong Xie, Xiangyi Kong, Xiangyi Kong, Hongnan Jiang, Jidong Gao, Jidong Gao

Subjects: Get full text

Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature by Guangjian Yang, Linyan Tian, Yan Wang

Subjects: Get full text

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer by Asiye Busra Boz Er

Subjects: “…HER2-positive breast cancer…”
Get full text

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer by Susan Dent, Avirup Guha, Heather Moore, Doris Makari, Rachael McCaleb, Irene Arias, Stella Stergiopoulos, Benjamin Li, Michael Fradley

Subjects: Get full text

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors by Neha Pathak, Abhenil Mittal, Sudhir Kumar, Chitrakshi Nagpal, Eitan Amir, Partha Haldar, Bharath B. Gangadharaiah, Akash Kumar, Ashutosh Mishra, Atul Batra

Subjects: Get full text

CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells by You-Yu Liu, Wei-Lun Huang, Sin-Tian Wang, Hui-Ping Hsu, Tzu-Ching Kao, Wei-Pang Chung, Kung-Chia Young

Subjects: “…anti-HER2 resistant breast cancer…”
Get full text

Immediate-Early Genes and Delayed Primary Response Genes Regulated by NmU in SKBR3 HER-2 Positive Breast Cancer Cell Line by Jessica Murphy, Sweta Rani

Subjects: Get full text